Energex proposes HemoModulation therapy for treatment of H1N1 swine
flu
8 May 2009
Energex Systems Inc. has announced that it has notified the FDA of
its interest in applying for an Emergency Use Approval that would permit
the company to offer its HemoModulation therapy for the treatment of
influenza type A(H1N1), otherwise known as swine flu.
HemoModulation therapy was shown to inactivate the virus in mice.
This same therapy has been under review by the FDA and is in human
clinical trials for Hepatitis C and HIV.
HemoModulation therapy is a process using precise amounts of UVC
energy on a small sample of the patient's blood to inactivate the
particular strain of virus that the patient is infected with, and
returning the blood to the body. The hypothesis is that UV inactivated
virus will serve as an autologous vaccine and boost the immune system of
the patient against their particular strain of virus.
The process takes approximately 30 minutes and can be administered in
an office, lab or any other healthcare facility.
In animal studies, says Thomas Petrie, the company’s Director of
Research & Development, the therapy produced discernable and substantial
improvement in both clinical disease and pulmonary function in mice
infected with the H1N1 virus.
Minimal clinical illness was observed up to 9 days post infection for
those animals that were treated. In contrast, the SHAM-treated animals
developed severe illness by day 6 that did not significantly resolve
through the 13-day course of the study.
As measured by pulmonary lung function testing, infected animals that
were treated with HemoModulation therapy exhibited a significantly
greater ability to breathe relative to their sham-treated counterparts
and pathological examination of lungs clearly indicated that treatment
significantly inhibited virus induced inflammation resulting in airways
that were for the most part, clear of inflammatory cells and cellular
debris.
In contrast, the lungs of the sham-treated animals had airways that
were filled with inflammatory cells and blood, and exhibited substantial
destruction of cells lining the airways.
Bookmark this page